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The problem of antibiotic resistance is not a new one. Multiple 
drug resistance in Escherichia coli was first observed in the 1950s. 
Transfer of resistance between species had also been observed by 
this time.[1] There has been evidence for the transfer of resistance 
genes between members of the human microbiota, as well as from 
livestock-associated bacteria to human-associated bacteria.[2] The 
presence of antimicrobial resistance genes even in non-pathogenic 
isolates therefore represents a problem, as these genes can easily be 
transferred to a pathogen.
Children acquire bacteria from their mother during birth,[3,4] and 
their gut microbiomes then undergo maturation during the first 
3  years of life.[5] The early colonisation and development of this 
dynamic environment may predispose individuals to differences 
in disease incidence and outcomes. Considering that intestinal 
infectious diseases are the leading cause of death in children aged 
<14  years in Limpopo Province, South Africa (SA),[6] and that 
resistance genes can be geographically distinct, identification and 
monitoring of resistance mechanisms is important in order to foster 
appropriate treatment regimens. We therefore decided to focus on 
community isolates from children as opposed to clinical isolates, 
which are often the source of strains in studies focused on resistant 
organisms.
The Etiology, Risk Factors, and Interactions of Enteric Infections 
and Malnutrition and the Consequences for Child Health and 
Development (MAL-ED) project was designed to look for correlations 
between factors present during childhood in developing regions, 
focusing on the relationship between enteric pathogen presence 
and growth and development outcomes. Each participant in MAL-
ED had stool samples taken on at least a monthly basis from birth 
until age 2 years, and information on health events such as the 
incidence of diarrhoea and exposure to antibiotics was collected. In 
addition, developmental milestone data for each participant were 
recorded, such as height, weight and cognitive ability. This rich 
data set allowed us to consider which antibiotics were most relevant 
to the community, as we had details of exposure for all the study 
participants (supplementary Table 1: Appendix 1). Penicillin-class 
antibiotics are the most frequently administered, so resistance to this 
class would be most detrimental to health outcomes; we therefore 
determined that beta-lactamase genes would be an appropriate area 
of focus.
Objective
To present data on E. coli strains isolated from stool samples collected 
as part of the MAL-ED study. The children from whom the strains 
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Background. Antibiotic resistance is a growing problem worldwide. Mechanisms of resistance vary, and some can confer resistance to 
multiple classes of antibiotics.
Objective. To characterise the antibiotic resistance profiles of Escherichia coli isolates obtained from stool samples of young rural children 
exposed or unexposed to antibiotics.
Methodology. The samples were collected from children aged 4 - 12 months who were participants in the Etiology, Risk Factors, and 
Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development (MAL-ED) project at the 
South Africa research site. We isolated 87 E. coli samples (clones) from 65 individual participants, all of which were subjected to disc 
diffusion assay to determine resistance. We characterised the minimum inhibitory concentration of antibiotics in a subset of strains as well 
as the mechanism by which these strains were resistant to beta-lactam antibiotics.
Results. Our results revealed high resistance rates to co-trimoxazole (54.0%), penicillin (47.1%) and tetracycline (44.8%) in our isolates, and 
indicated that the beta-lactamase TEM-1 is a prevalent source of beta-lactam resistance. We also identified two isolates with the extended-
spectrum beta-lactamase CTX-M-14.
Conclusions. This study identified antibiotic-resistant E. coli in children with and without prior exposure to antibiotics, with some 
isolates showing resistance to multiple classes of antibiotics. Clinicians should bear in mind that transmission of extended-spectrum beta-
lactamase-resistant E. coli exists at the community level, and that children as young as 2 years may be harbouring these resistant phenotypes.
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were isolated ranged in age from 4 to 12 months and had varying 
histories in terms of antibiotic exposure and diarrhoeal events. The 
antibiotic susceptibilities of the isolates were characterised, along with 
their minimum inhibitory concentrations (MICs) and identification 
of some of the beta-lactamase genes responsible. For beta-lactam-
resistant isolates, we tested for variants of several narrow-spectrum 
beta-lactamases (TEM, SHV and OXA), as well as some variants of 
the CTX-M extended-spectrum beta-lactamase (ESBL) type.
Methods
Ethical considerations
The study protocol was approved by the Research Ethics Committee 
of the University of Venda, SA (ref. no. SMNS/09/MBY/004). 
Permission was obtained from the Department of Health, Limpopo 
Province (ref. no. 4/2/2), SA. Signed informed consent was obtained 
from the parents or legal guardians of all study subjects prior to 
enrolment and sample collection.
Strain isolation and growth
E. coli strains were isolated from stool samples collected as part of the 
MAL-ED study, and in addition E. coli ATCC 25922 (Microbiologics, 
USA) was maintained as a control strain. Initial isolation of lactose 
fermenters (pink colonies) was performed on MacConkey agar 
(Neogen, USA), followed by screening on EMB agar (Neogen, 
USA), on which E. coli produce a characteristic green sheen. In 
total, 87 strains were isolated from 65 study participants. Cultures 
were maintained in nutrient broth (Oxoid, UK) or on nutrient agar 
(Neogen, USA) at 37°C.
Antibiotic susceptibility testing
Antibiotic susceptibility testing was performed using the disc diffusion 
assay.[7] Briefly, colonies were resuspended in sterile saline to a 
McFarland standard of 0.5, and were uniformly spread on Mueller-
Hinton agar (Mast Diagnostics, UK) using sterile cotton swabs. 
Antibiotic discs (Mast Diagnostics, UK) were dispensed using the 
Discmaster 3 Dispenser (Mast Diagnostics, UK), and plates were 
incubated overnight at 37°C. Zones of inhibition were then measured 
against a black, non-reflecting background. E. coli ATCC 25922 was 
utilised as a control strain to ensure that zones of inhibition were 
within an appropriate range, according to Clinical and Laboratory 
Standards Institute (CLSI) standards.[7] The CLSI zone diameter 
interpretive criteria for Enterobacteriaceae were used for interpretation 
of all antibiotic inhibitory zones except those of the macrolides. For 
azithromycin, a zone ≤13 mm was considered to indicate resistance, a 
zone of 14 - 17 mm was considered the intermediate range, and a zone 
≥18 mm was considered to indicate sensitivity.
Detection and identification of beta-lactamases
Multiplex polymerase chain reactions (PCRs) for detection of beta-
lactamase genes were designed by Dallenne et al.[8] The first multi plex 
PCR amplified  blaTEM/blaSHV/blaOXA-1-like genes using the follow-
ing primers: MultiTSO-T_for CATTTCCGTGTCGCCCTTATTC 
(0.4 µM)/MultiTSO-T_rev CGTTCATCCATAGTTGCCTGAC 
(0.4 µM) – product size 800 bp, MultiTSO-S_for 
AGCCGCTTGAGCAAATTAAAC (0.4 µM)/MultiTSO-S_rev 
ATCCCGCAGATAAATCACCAC (0.4 µM) – product size 713 bp, 
and MultiTSO-O_for GGCACCAGATTCAACTTTCAAG (0.4 µM)/
MultiTSO-O_rev GACCCCAAGTTTCCTGTAAGTG (0.4 µM) – 
product size 564 bp. The second amplified blaCTX-M phylogenetic 
groups 1, 2 and 9 using the following primers: MultiCTXMGp1_for 
TTAGGAARTGTGCCGCTGYA (0.4 µM)/MultiCTXMGp1-2_rev 
CGATATCGTTGGTGGTRCCAT (0.2 µM) – product size 688 
bp, MultiCTXMGp2_for CGTTAACGGCACGATGAC (0.2 
µM)/MultiCTXMGp1-2_rev CGATATCGTTGGTGGTRCCAT 
(0.2 µM) – product size 404 bp, and MultiCTXMGp9_for 
TCAAGCCTGCCGATCTGGT (0.4 µM)/MultiCTXMGp9_rev 
TGATTCTCGCCGCTGAAG (0.4 µM) – product size 561 bp. PCRs 
were performed in duplicate, one replicate using DNA isolated with 
the GeneJET Plasmid Miniprep Kit (Thermo Scientific, USA) and 
one using colonies resuspended in 100 µL of water and subjected to 
heating at 95°C for 10 minutes.
PCRs were performed using DreamTaq Green Master Mix (Thermo 
Scientific, USA) in 50 µL reactions, using the primer concentrations 
specified above. The amplification reaction was performed as in 
Dallenne et al.:[8] 94°C for 10 minutes; [94°C for 40 seconds, 60°C for 
40 seconds and 72°C for 1 minute] × 30 cycles; 72°C for 7 minutes. 
Amplified beta-lactamase genes were visualised under ultraviolet 
light following separation on a 2% agarose gel containing ethidium 
bromide, along with a GeneRuler 100 bp Plus ladder (Thermo 
Scientific, USA). Products were purified using the GeneJET PCR 
Purification Kit (Thermo Scientific, USA) and sent for sequencing 
(Inqaba Biotec, SA).
Sequencing results were analysed using Geneious 7 (http://
www.geneious.com), and the data were searched using the NCBI 
Nucleotide BLAST Megablast tool (http://blast.ncbi.nlm.nih.gov/), 
optimised for highly similar sequences.
Minimum inhibitory concentrations
MICs were determined using MIC Test Strips (Liofilchem, Italy). 
Antimicrobial susceptibility testing was performed according to 
the manufacturer’s guidelines. Briefly, colonies of each strain were 
suspended in sterile saline solution to achieve a 0.5 McFarland 
standard turbidity level, and were uniformly spread on Mueller-
Hinton agar (Mast Diagnostics, UK) using sterile cotton swabs. Once 
the agar surface was completely dry, an MIC test strip was applied to 
each plate with sterile forceps and the plates were incubated at 37°C 
for 18 - 24 hours. The MIC was read where inhibition of growth 
intersected the strip.
Results
Antibiotic susceptibility of isolates
Each E. coli clone was tested for susceptibility to 13 antibiotics or 
combination therapies using the disc diffusion method.[7] Results 
of testing are shown in Table 1. The highest incidence of resistance 
was to the trimethoprim-sulfamethoxazole combination antibiotic 
(co-trimoxazole), with 54.0% of isolates showing resistance. The 
second highest incidence of resistance was towards penicillin-class 
antibiotics, with 47.1% of isolates showing resistance to ampicillin 
and amoxicillin. Much of this resistance appeared to be reversed by 
the inclusion of a beta-lactamase inhibitor, clavulanic acid. We did 
not observe resistance to several antibiotics including imipenem, 
ciprofloxacin, and both aminoglycosides tested. Although not 
typically included in Gram-negative susceptibility studies owing to 
their inefficient penetration of the cell wall,[9] a macrolide antibiotic 
was tested, as E. coli has been shown to be a potential reservoir for 
macrolide resistance genes.[10] The azithromycin results are reported 
in Table 1, and indicate that ~20% of isolates show some enhanced 
resistance to this class.
Isolates showing no resistance were most abundant (n=29), whereas 
the second-largest subset of isolates (n=24) showed resistance to three 
antibiotics, indicating that resistance to more than one antibiotic is 
more common than resistance to one (n=14 isolates) or two (n=7). 
Additional information detailing which resistances were observed in 
which clones can be found in supplementary Table 2 (Appendix 2).
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Presence and identity of beta-lactamase genes
All strains resistant to penicillins were subjected to multiplex PCR 
amplification to determine which beta-lactamases were present. The 
multiplex PCRs, originally designed by Dallenne et al.,[8] can identify 
the presence of certain TEM, SHV, OXA and CTX-M variants. TEM, 
SHV and OXA are narrow-spectrum beta-lactamases, whereas 
CTX-M is an ESBL. The 41 strains tested included one isolate with 
resistance to the combination treatment of amoxicillin + clavulanic 
acid. Results of multiplex PCR are shown in Table 2. A subset 
of the PCR products were sequenced and analysed by BLAST, 
which revealed that both of the CTX-M group 9 beta-lactamases 
present were in fact CTX-M-14. As for the samples positive for 
TEM, products from 18 clones were sent for sequencing, which 
revealed that all 18 were TEM-1. This result is not surprising 
considering that this is the most frequently observed resistance gene 
in enterobacteria.[11] The sequences of the amplified regions can be 
found in supplementary Table 3 (Appendix 3).
Minimum inhibitory concentrations
MIC ranges were 0.016 - 0.094 μg/mL for ciprofloxacin, 0.125 - 
4.0 μg/mL for imipenem, 0.38 - 2 μg/mL for gentamicin, 1.5 - 3 μg/
mL for amikacin, 1.0 - 24.0 μg/mL for amoxicillin + clavulanic 
acid, 1.5 - 32 μg/mL for azithromycin, 0.047 - 0.125 μg/mL for 
cefotaxime, 4.0 - 48 μg/mL for chloramphenicol and 0.125 - 24.0 μg/
mL for nalidixic acid (Table 3). Some MIC values outside the test 
range were observed for a subset of strains tested when exposed to 
chloramphenicol and nalidixic acid.
Strains showing resistance phenotypes to beta-lactam antibiotics 
were subjected to multiplex PCR to determine the presence of 
specific beta-lactamase genes. A subset of these products was 
sequenced, allowing identification of the specific beta-lactamase gene 
using BLAST.
Discussion and conclusion
When deciding which antibiotics to test in the disc diffusion assays, 
we considered the most frequently used antibiotics in the SA site 
MAL-ED participant group (supplementary Table 1). This provided 
useful information on the local clinical usage of various classes of 
antibiotics, with the penicillin class being most common, followed by 
sulfonamides, macrolides and others. With penicillin-class antibiotics 
being most commonly employed in treatment of illness, resistance to 
this class would have the most negative impact, so we chose to focus 
on resistance mechanisms to this class. Penicillin resistance was in 
fact the second most prevalent in our study, after co-trimoxazole 
resistance, which is a worrying trend considering the common use of 
penicillin in the management of bacterial infections.
Multidrug resistance is resistance to multiple classes of antibiotics. 
Of the 87 isolates tested, 2 showed resistance to five antibiotics 
(ampicillin/amoxicillin, co-trimoxazole, chloramphenicol, tetra-
cycline and nalidixic acid) and 11 showed resistance to four 
antibiotics. Interestingly, the two most multidrug-resistant isolates 
were from individuals with no reported exposure to antibiotics. The 
two strains that harbour the CTX-M-14 resistance gene both show 
resistance to three antibiotics: cefotaxime, ampicillin/amoxicillin 
and tetracycline. Although antibiotic exposure increases the 
selective pressure for organisms to develop and maintain antibiotic-
resistant elements, the presence of resistance genes apparently 
does not necessarily correlate with prior exposure to antimicrobial 
agents.
Table 1. Results of disc diffusion tests for antimicrobial resistance
Class of antibiotic Antibiotic (μg*)
Resistant,
n (%)†
Intermediate,
n (%)†
Sensitive,
n (%)†
Penicillins Ampicillin (10) or amoxicillin (10)‡ 41 (47.1) 0 46 (52.9)
Amoxicillin (20) + 
clavulanic acid (10)
1 (1.2) 1 (1.2) 85 (97.7)
Cephalosporins Cefotaxime (30) 2 (2.3) 0 85 (97.7)
Carbapenems Imipenem (10) 0 0 87 (100)
Quinolones Nalidixic acid (30) 5 (5.7) 4 (4.6) 78 (89.7)
Fluoroquinolones Ciprofloxacin (5) 0 0 87 (100)
Folate pathway inhibitor/
sulfonamides
Trimethoprim (1.25) + 
sulfamethoxazole (23.75)
47 (54.0) 0 40 (46.0)
Phenicols Chloramphenicol (30) 9 (10.3) 0 78 (89.7)
Tetracyclines Tetracycline (30) 39 (44.8) 0 48 (55.2)
Aminoglycosides Gentamicin (10) 0 0 87 (100)
Amikacin (30) 0 0 87 (100)
Macrolides Azithromycin (15) 10 (11.5) 7 (8.1) 70 (80.5)
*The mass of the antibiotic, or the mass of each component for mixtures.
†Number of clones that exhibit a given phenotype, and percentage of all clones showing this phenotype.
‡Although results of ampicillin testing can be used to predict results for amoxicillin,[7] both were included. The results for the two were identical.
Table 2. Beta-lactamases present in penicillin-resistant strains
Beta-lactamase 
gene*
Positive clones,
n (%) Gene identity
TEM (includes 
TEM-1, TEM-2)
39 (95.1) 18/39 tested, all 
TEM-1
CTX-M group 9 
(includes CTX-M-9 
and CTX-M-14)
2 (4.9) 2/2 tested, both 
CTX-M-14
*Other beta-lactamases tested but not identified in these samples include variants of SHV, 
OXA, and CTX-M groups 1 and 2.
208       March 2017, Vol. 107, No. 3
RESEARCH
To characterise the range of MICs for our 
isolates, a subset was tested using MIC test 
strips. Results for amikacin, amoxicillin  + 
clavulanic acid, chloramphenicol, cipro-
floxacin, cefotaxime, gentamicin and nalidixic 
acid were all consistent with the disc diffusion 
assay results. For imipenem, ~16% of the MIC 
results indicated resistance where the disc 
diffusion assay had not indicated this, as did 
~7% for azithromycin. This indicates that the 
proportion of resistant isolates may actually 
be higher than we reported. There was also 
one azithromycin test that showed resistance 
in the disc diffusion and sensitivity in the 
MIC testing.
Some participants in the MAL-ED study 
went on to develop severe acute mal-
nutrition. Treatment for this condition 
often involves administration of antibiotics, 
as recommended by the W orld Health 
Organization (WHO); however, there is no 
strong evidence that this is the best course 
of action.[12] Considering our evidence that 
even without antibiotic exposure, children at 
risk of malnutrition often harbour resistance 
genes, it seems that the introduction of 
additional selective pressure could actually 
contribute to ill health rather than recovery. 
A 2014 study[13] found that the diversity of 
antibiotic resistance genes in the human 
gut microbiota appears to increase with age, 
although they did not look at individuals 
<3 years of age. This would indicate that 
even without antibiotic administration, the 
burden of resistance would increase over 
time.
The diversity of beta-lactamases is high, 
and many novel variants are reported year 
after year. In the early 1990s there were 
fewer than 150 known beta-lactamases, and 
by 2009, over 890 unique beta-lactamase 
sequences had been identified.[14] New 
enzymes often emerge in isolated areas and 
go on to expand their host range and also 
their geographical range. TEM-1, which 
we observed in a majority of penicillin-
resistant isolates, is the most commonly 
found secondary beta-lactamase in ampi-
cillin-resistant E. coli,[11] with much greater 
prevalence than TEM-2, SHV and OXA-1 
(the other narrow-spectrum beta-lactamases 
that we tested for).[15] ESBLs are beta-
lactamases with enhanced activity against 
cephalosporins, early examples of which 
were similar to TEM and SHV. The CTX-
M-type ESBL was first observed in the late 
1980s, and is not TEM- or SHV-derived.[16]
Although previous studies in SA found 
examples of multiple ESBLs being produced 
by clinical isolates,[17-20] the first report of 
CTX-M-type ESBLs was not until 2003, 
where CTX-M-2 and CTX-M-3 were found 
in Klebsiella pneumoniae.[21] Since then, 
other CTX-M types have been found in 
SA, including CTX-M-14, CTX-M-15 and 
CTX-M-37.[22-25] The WHO reports that in 
the African Region there are insufficient 
data concerning antibiotic resistance,[26] so 
additional reports such as this are important 
in this regard. The data presented are limited 
to the MAL-ED SA Dzimauli community 
study site of Limpopo Province.[27] However, 
our identification of the CTX-M-14 ESBL in 
community E. coli isolates, even in young 
children who have not received antibiotics, 
adds to the greater picture of the antibiotic 
resistance landscape in SA and in the African 
Region.
The prescribing patterns of antibiotics, 
either through excessive use or through 
sub-therapeutic doses, in addition to the 
use of antibiotics in animal production, 
are factors known to contribute to the 
development and spread of antibiotic resis-
tance at community level. Our finding has 
clinical relevance. Firstly, it adds to the 
body of evidence on the spread of antibiotic 
resistance in rural communities, and secon-
dly, it supports the increasing need for a 
reduction in the frequency of empirically 
prescribing antibiotics, a common practice 
Table 3. MIC (μg/mL) of different antibiotics against E. coli clones
Clone 
no. CIP IMI CN AK AUG AZM CTX C NA
91 0.023 0.5 0.75 2 6 256 0.047 8 3
92 0.023 0.19 0.75 2 6 2 0.094 4 4
96 0.023 0.125 0.75 2 3 1.5 0.064 6 3
98 0.094 0.38 0.5 2 6 8 0.047 8 4
102 0.023 0.25 0.75 2 3 256 0.094 6 6
111 0.023 0.25 0.5 2 6 24 0.094 8 4
112 0.016 1 1 3 6 32 0.094 256 2
115 0.019 4 0.75 3 6 8 0.064 6 256
116.1 0.023 0.19 0.75 1.5 3 1.5 0.064 6 4
116.2 0.023 0.19 0.75 2 6 1.5 0.094 4 3
120 0.016 0.25 1.5 1.5 8 256 0.125 8 4
121 0.023 1 0.75 2 1 4 0.047 8 4
127 0.023 4 0.75 3 12 32 0.094 8 6
130 0.023 3 1 2 4 3 0.047 6 4
131 0.094 3 0.75 2 24 8 0.125 8 6
132 0.023 3 0.75 3 3 16 0.064 8 4
133 0.023 0.25 0.75 2 8 8 0.064 8 6
138 0.023 0.38 0.75 2 3 4 0.064 6 6
140 0.023 4 0.75 2 3 4 0.094 8 4
141 0.023 0.25 0.75 1.5 8 6 0.094 6 4
145 0.023 0.25 0.75 3 6 4 0.047 8 6
151 0.023 0.19 0.75 3 6 8 0.064 8 6
158.1 0.032 0.5 2 3 4 4 0.094 24 16
158.2 0.047 4 0.75 3 6 16 0.094 48 24
159 0.023 1.5 0.75 2 4 8 0.064 12 3
163 0.012 0.25 1.5 3 6 8 0.064 8 3
167 0.023 1 1.5 2 12 256 0.125 12 6
172 0.023 0.38 0.75 3 4 6 0.064 12 6
173 0.016 4 1.5 3 16 256 0.125 12 12
181 0.016 0.38 0.75 1.5 8 6 0.125 6 6
CIP = ciprofloxacin; IMI = imipenem; CN = gentamicin; AK = amikacin; AUG = amoxicillin + clavulanic acid;  
AZM = azithromycin; CTX = cefotaxime; C = chloramphenicol; NA= nalidixic acid.
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in communities without diagnostic laboratory support. Discouraging 
empirical prescription has been proposed in the SA national 
approach to ‘antibiotic stewardship’.[28] In conclusion, clinicians and 
public health practitioners should bear in mind that transmission of 
ESBL-resistant E. coli exists at the community level and that children 
as young as 2 years, even without prior exposure to antibiotics, may 
be harbouring these resistant phenotypes, an awareness that should 
guide prescription practices.
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Supplementary Table 1. Antibiotic exposure of SA site MAL-ED participants and antibiotics used in the study*
Class Days of exposure Representative antibiotic(s) tested
Penicillins 3 083 Ampicillin, amoxicillin, amoxicillin + clavulanic acid
Sulfonamides 395 Trimethoprim + sulfamethoxazole
Macrolides 289 Azithromycin, erythromycin
Metronidazole 140 -
Other/unknown 107 Imipenem, chloramphenicol, gentamicin, amikacin
Tetracyclines 27 Tetracycline
Cephalosporins 6 Cefotaxime
Fluoroquinolones 1 Ciprofloxacin, nalidixic acid
*This table lists the total days of exposure to different classes of antibiotics for all SA site participants in the MAL-ED study. This provided information on the most frequently used antibiotics in 
the community, which informed our selection of antibiotics.
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Supplementary Table 3. Derived nucleotide sequences of beta-lactamase genes studied*
Strains tested Group Sequence of beta-lactamase gene 
Clones 5.2 and 25 CTX-M-14 TTGATTCTCGCCGCTGAAGCCAGCACATCGCGGCGGCTCTCTGCGTTCTGTTGCGGCTGGGT
AAAATAGGTCACCAGAACCAGCGGCGCACGACCCTGCGGCCAGATCACCGCAATATCATTGG
TGGTGCCGTAGTCGCCGCTGCCGGTCTTATCACCCACAGTCCACGACGTCGGTAAGCCGGCC
CGAATGCTGGCTGCGCCGGTCGTATTGCCTTTGAGCCACGTCACCAACTGCGCCCGCTGGGT
TTCGCCCAGCGCATGACCCAGCGTAAGCTGACGCAACGTCTGCGCCATCGCCCGCGGCGTGG
TGGTGTCTCTCGGGTCGCCGGGAATGGCGGTATTCAGCGTAGGTTCAGTGCGATCCAGACGA
AACGTCTCATCGCCGATCGCGCGGGCAAAAGCCGTCACGCCTCCCGGGCCACCGAGCTGGG
CAATCAATTTGTTCATGGCGGTATTGTCGCTGTACTGCAACGCGGCCGCGCTCAGTTCTGC
CAGCGTCATTGTGCCGTTGACGTGTTTTTCGGCAATCGGATTGTAGTTAACCAGATCGGC
AGGCTTGAA
Clones 11.2, 12, 14, 
17, 22, 29, 30, 31, 
39, 46, 47, 61, 63, 
67, 73, 78, 89, 112
TEM-1 TGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCACCCAGAAACG
CTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGAT
CTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTT
TTAAAGTTCTGCTATGTGGTGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCG
CCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACG
GATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCTGCC
AACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGG
GATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGA
GCGTGACACCACGATGCCTGCAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAAC
TACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGA
CCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTG
AGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCG
TAGTTATCTACACGACGGGGAGTCAGGCAACTATGGG
*This table lists the sequences obtained for the beta-lactamase gene regions amplified by PCR. The first column indicates which clones these sequences were amplified from, the second column 
indicates which beta-lactamase group these genes fall into (as determined by BLAST), and the third column contains the sequence information. No variation in sequence was observed for clones 
that fell into the same beta-lactamase group.
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